Allogene Therapeutics, Inc. Operating Lease, Expense
Allogene Therapeutics, Inc. (ALLO) reported Operating Lease, Expense of $2.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-12
- Allogene Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $1.08M, a 5.84% decline year-over-year.
- Allogene Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $1.07M, a 5.40% decline year-over-year.
- Allogene Therapeutics, Inc. operating lease, expense for the quarter ending 2025-12-31 was $1.05M, a 6.18% decline year-over-year.
- Allogene Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $1.03M, a 29.09% decline year-over-year.
- Allogene Therapeutics, Inc. operating lease, expense for fiscal 2025 was $4.36M, a 17.27% decline from fiscal 2024.
- Allogene Therapeutics, Inc. operating lease, expense for fiscal 2024 was $5.26M, a 20.77% decline from fiscal 2023.
- Allogene Therapeutics, Inc. operating lease, expense for fiscal 2023 was $6.64M, a 173.08% increase from fiscal 2022.
- Allogene Therapeutics, Inc. operating lease, expense for fiscal 2022 was $2.43M, a 6.82% decline from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.15M 10-Q · filed 2026-08-12 | $3.20M derived: sum of 3 quarters · filed 2026-08-12 | $4.23M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $1.07M 10-Q · filed 2026-05-13 | $2.12M derived: sum of 2 quarters · filed 2026-05-13 | $3.15M derived: sum of 3 quarters · filed 2026-05-13 | $4.29M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.08M derived: sum of 2 quarters · filed 2026-03-12 | $3.23M derived: sum of 3 quarters · filed 2026-08-12 | $4.36M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.18M derived: sum of 2 quarters · filed 2026-08-12 | $3.31M 10-Q · filed 2025-11-06 | $4.42M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.28M 10-Q · filed 2026-08-12 | $3.39M derived: sum of 3 quarters · filed 2026-08-12 | $4.85M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $1.13M 10-Q · filed 2026-05-13 | $2.25M derived: sum of 2 quarters · filed 2026-05-13 | $3.70M derived: sum of 3 quarters · filed 2026-05-13 | $5.24M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.57M derived: sum of 2 quarters · filed 2026-03-12 | $4.11M derived: sum of 3 quarters · filed 2026-03-12 | $5.26M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.99M derived: sum of 2 quarters · filed 2025-11-06 | $4.15M 10-Q · filed 2025-11-06 | $10.29M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.69M 10-Q · filed 2025-08-13 | $8.83M derived: sum of 3 quarters · filed 2025-08-13 | $8.98M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $1.15M 10-Q · filed 2025-05-13 | $7.29M derived: sum of 2 quarters · filed 2025-05-13 | $7.44M derived: sum of 3 quarters · filed 2025-05-13 | $7.59M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $6.29M derived: sum of 2 quarters · filed 2025-03-13 | $6.44M derived: sum of 3 quarters · filed 2025-03-13 | $6.64M 10-K · filed 2025-03-13 | $642.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | $147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $297.00K derived: sum of 2 quarters · filed 2023-11-02 | $504.00K 10-Q · filed 2023-11-02 | $744.00K derived: sum of 4 quarters · filed 2024-03-14 | |
| 2023-06-30 | $150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $357.00K 10-Q · filed 2023-08-02 | $597.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.15M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2023-03-31 | $207.00K 10-Q · filed 2023-05-03 | $447.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.00M derived: sum of 3 quarters · filed 2024-03-14 | $2.17M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-12-31 | $240.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $793.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.97M derived: sum of 3 quarters · filed 2024-03-14 | $2.43M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $553.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.73M derived: sum of 2 quarters · filed 2023-11-02 | $2.19M 10-Q · filed 2023-11-02 | $2.18M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $1.64M 10-Q · filed 2023-08-02 | $1.63M derived: sum of 3 quarters · filed 2024-03-14 | $1.86M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $466.00K 10-Q · filed 2023-05-03 | $455.00K derived: sum of 2 quarters · filed 2024-03-14 | $683.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.07M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | -$11.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $217.00K derived: sum of 2 quarters · filed 2024-03-14 | $604.00K derived: sum of 3 quarters · filed 2024-03-14 | $2.61M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $615.00K derived: sum of 2 quarters · filed 2022-11-02 | $2.62M 10-Q · filed 2022-11-02 | $5.34M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | $387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.39M 10-Q · filed 2022-08-09 | $5.11M derived: sum of 3 quarters · filed 2024-03-14 | $5.29M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $2.01M 10-Q · filed 2022-05-04 | $4.72M derived: sum of 2 quarters · filed 2024-03-14 | $4.90M derived: sum of 3 quarters · filed 2024-03-14 | $5.24M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $2.71M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $2.90M derived: sum of 2 quarters · filed 2024-03-14 | $3.24M derived: sum of 3 quarters · filed 2024-03-14 | $3.96M 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $522.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.24M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $342.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.06M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $718.00K 10-Q · filed 2021-05-05 | ||||
| 2019-09-30 | $4.83M 10-Q · filed 2020-11-04 | ||||
| 2019-03-31 | $1.00M 10-Q · filed 2019-05-07 | ||||
| 2018-09-30 | $1.00M 10-Q · filed 2018-11-21 | $1.70M 10-Q · filed 2018-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |